Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01328535 · ClinicalTrials.gov registry record · Phase 2
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
A Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01328535 is a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma that has completed, run by Mayo Clinic. The registered enrollment target is 25 participants, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01328535, a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies individualized temozolomide (TMZ) in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as TMZ, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving TMZ at different times, which are determined individually for each patient based on the phase (biorhythm) of the immune system response against the tumor may allow for a better drug response and may kill more tumor cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- DRUG temozolomide
- OTHER flow cytometry
- OTHER staining method
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-01 |
| Est. Completion | 2018-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01328535
The ClinicalTrials.gov registry entry for NCT01328535 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (85% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01328535 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01328535 about?
NCT01328535 is a clinical study titled "Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery". This clinical trial studies individualized temozolomide (TMZ) in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as TMZ, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividin...
What is the current status of trial NCT01328535?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-01. Estimated completion is 2018-07-11.
What conditions does trial NCT01328535 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Melanoma.
What interventions are being tested in trial NCT01328535?
The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), temozolomide (DRUG), flow cytometry (OTHER), staining method (OTHER).
Who is sponsoring clinical trial NCT01328535?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01328535 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.